Showing results (511-520 of 652) with videos related to
Sort By:
Pageof 66
Journal of Crohn'S & Colitis|March 3, 2022
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term ExtensionMaria T Abreu, David S Rowbotham, Silvio Danese, et al.Inflammatory Bowel Diseases|May 3, 2018
Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter StudyEmma Calabrese, Torsten Kucharzik, Christian Maaser, et al.Psychiatry Investigation|March 8, 2014
Low-dose acetazolamide in the treatment of premenstrual dysphoric disorder: a case seriesGabriele Sani, Georgios D Kotzalidis, Isabella Panaccione, et al.Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.Journal of the Canadian Association of Gastroenterology|November 10, 2021
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and MedicationsLaura E Targownik, Charles N Bernstein, Peter L Lakatos, et al.Inflammatory Bowel Diseases|June 17, 2016
Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel DiseaseMichael R Tom, Ji Li, Aito Ueno, et al.Inflammatory Bowel Diseases|June 1, 2016
Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's DiseaseJi Li, Aito Ueno, Miriam Fort Gasia, et al.Contemporary Clinical Trials Communications|December 17, 2025
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's diseaseSilvio Danese, Bruce E Sands, Brian G Feagan, et al.The Lancet. Gastroenterology & Hepatology|September 8, 2023
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance studySéverine Vermeire, Silvio Danese, Wen Zhou, et al.Gastroenterology|March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flavio Steinwurz, et al.Pageof 66